MESO FY 2018 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+618.9% YoY

Gross Profit

$12M68.2% margin

Operating Income

-$77M-446.0% margin

Net Income

-$35M-203.5% margin

EPS (Diluted)

$-0.76

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$75M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$692M

Total Liabilities

$146M

Stockholders' Equity

$546M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$2M	+618.9%
Gross Profit	$12M	-$10M	+222.6%
Operating Income	-$77M	-$90M	+14.1%
Net Income	-$35M	-$77M	+54.1%